#United States #Patent Infringement #PainTEQ #Morgantown #Omnia Medical

Omnia Medical and PainTEQ Resolve Long-Standing Disputes

On June 16, 2025, a significant turning point emerged in the ongoing legal saga between Omnia Medical and PainTEQ. After several years marred by multiple lawsuits and counterclaims, both parties have reached a resolution that aims to address the breaches and patent infringements that have shaped this contentious relationship.

The legal battle's roots trace back to June 2020 when PainTEQ levied business-related claims that eventually spiraled into a much wider confrontation. Omnia Medical fired back with counterclaims that accused PainTEQ of infringing on key intellectual property rights and breaching contractual terms. Throughout this titanic struggle, allegations concerning the misuse of Omnia's PsiF trademark and infringements of its design patents came to the forefront, leading to a series of complex litigation developments.

As stipulated in the newly agreed settlement, PainTEQ has admitted to violating the terms of the Stocking Agreement and acknowledged that its Gen 2 cannula violated Omnia's D232 design patent. Both companies have now expressed optimism for the future, emphasizing their desire to move forward with their operations without the burden of ongoing legal entanglements. Troy Schifano, CEO of Omnia Medical, voiced a commitment to increased transparency within the pain management industry, highlighting the need for clarity amidst the confusion that has often obscured these types of issues. "The agreed-upon settlement in this suit should bring some long overdue transparency and visibility to the pain space," Schifano stated. He believes that the resolution will compel medical practitioners to conduct thorough research on the companies they choose to collaborate with.

In hindsight, this settlement not only puts an end to the prolonged disputes but also reinforces Omnia Medical's status as an innovator in the field of interventional pain management. The company's historical contribution to posterior sacroiliac (SI) joint arthrodesis since their debut procedure in 2013 has been evident, cementing their place as a leader in this specialized area. The CIO of Omnia Medical, Chris Henneforth, pointed to the company’s recent advancements, including the introduction of PsiF90 and PsiFGuard technology, underscoring their commitment to pushing the boundaries of medical innovation. Henneforth’s comments underscore the confidence that the company intends to maintain in its competitive capabilities while further paving the way for the clinical validation of its products.

As both companies look towards a more harmonious future, those interested in the specific details of the resolved lawsuits can find information about consolidated federal court cases through the official court website. Reference to the US District Court for the Middle District of Florida, particularly case number 820-cv-02805-VMC-AAS, will yield necessary documentation for further inquiries.

The closure of the dispute between Omnia Medical and PainTEQ illustrates the potential for resolution even amid challenging legal circumstances. Market observers will undoubtedly notice the impact of this settlement on industry dynamics, especially as the medical community increasingly demands accountability and integrity from its corporate partners. As both companies prepare to resume normal business operations, the impact of this resolution should play a significant role in shaping the landscape of pain management solutions compatible with their reputations moving forward.

For further media inquiries, journalists can contact Christopher Henneforth at Omnia Medical’s dedicated media address.